Embecta (EMBC) Revenue & Revenue Breakdown
Embecta Revenue Highlights
Latest Revenue (Y)
$1.12B
Latest Revenue (Q)
$272.50M
Main Geography (Y)
UNITED STATES
Embecta Revenue by Period
Embecta Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-09-30 | $1.12B | -0.77% |
2022-09-30 | $1.13B | -3.05% |
2021-09-30 | $1.17B | 7.32% |
2020-09-30 | $1.09B | -2.12% |
2019-09-30 | $1.11B | - |
Embecta Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | $272.50M | -5.12% |
2024-03-31 | $287.20M | 3.57% |
2023-12-31 | $277.30M | -1.63% |
2023-09-30 | $281.90M | -1.47% |
2023-06-30 | $286.10M | 3.25% |
2023-03-31 | $277.10M | 0.51% |
2022-12-31 | $275.70M | 0.40% |
2022-09-30 | $274.60M | -5.67% |
2022-06-30 | $291.10M | 6.05% |
2022-03-31 | $274.50M | -5.12% |
2021-12-31 | $289.30M | -3.73% |
2021-09-30 | $300.50M | 1.86% |
2021-06-30 | $295.00M | 3.80% |
2021-03-31 | $284.20M | -0.39% |
2020-12-31 | $285.30M | 51.11% |
1968-12-31 | $188.80M | - |
Embecta Revenue Breakdown
Embecta Revenue Breakdown by Country
Annual Revenue by Country
Country | Sep 23 | Sep 22 |
---|---|---|
UNITED STATES | $601.40M | $600.30M |
Non-US | $519.40M | $529.20M |
Quarterly Revenue by Country
Country | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 |
---|---|---|---|---|---|---|---|---|---|---|
UNITED STATES | $147.60M | $148.60M | $151.80M | $153.90M | $146.40M | $149.30M | $149.90M | $158.00M | $139.80M | - |
Non-US | $139.60M | $128.70M | $130.10M | $132.20M | $130.70M | $126.40M | $124.70M | $133.10M | $134.70M | $138.40M |
United States of America, Dollars | - | - | - | - | - | - | - | - | - | $150.90M |
Embecta Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
BAX | Baxter | $14.81B | $3.59B |
ALC | Alcon | $10.09B | $2.46B |
RMD | ResMed | $4.69B | $1.22B |
COO | Cooper Companies | $3.59B | $1.00B |
ATR | AptarGroup | $3.49B | $909.29M |
TFX | Teleflex | $2.97B | $764.38M |
WST | West Pharmaceutical Services | $2.95B | $746.90M |
NVST | Envista | $2.57B | $884.70M |
ICUI | ICU Medical | $2.26B | $596.46M |
HAE | Haemonetics | $1.31B | $336.17M |
MMSI | Merit Medical Systems | $1.26B | $339.85M |
EMBC | Embecta | $1.12B | $272.50M |
ATRC | AtriCure | $399.25M | $115.91M |
ANGO | AngioDynamics | $303.91M | $67.49M |
AKYA | Akoya Biosciences | $96.63M | $23.16M |
ATRI | Atrion | - | $48.77M |
EMBC Revenue FAQ
What is Embecta’s yearly revenue?
Embecta's yearly revenue for 2023 was $1.12B, representing a decrease of -0.77% compared to 2022. The company's yearly revenue for 2022 was $1.13B, representing a decrease of -3.05% compared to 2021. EMBC's yearly revenue for 2021 was $1.16B, representing an increase of 7.32% compared to 2020.
What is Embecta’s quarterly revenue?
Embecta's quarterly revenue for Q3 2024 was $272.5M, a -5.12% decrease from the previous quarter (Q2 2024), and a -4.75% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $287.2M, a 3.57% increase from the previous quarter (Q1 2024), and a 3.64% increase year-over-year (Q2 2023). EMBC's quarterly revenue for Q1 2024 was $277.3M, a -1.63% decrease from the previous quarter (Q4 2023), and a 0.58% increase year-over-year (Q1 2023).
What is Embecta’s revenue growth rate?
Embecta's revenue growth rate for the last 3 years (2021-2023) was -3.79%, and for the last 5 years (2019-2023) was 1.06%.